[Retracted] Effects of Xuefu Zhuyu Granules on Patients with Stable Coronary Heart Disease: A Double-Blind, Randomized, and Placebo-Controlled Study

Table 1

Baseline characteristics of stable CHD patients receiving Xuefu Zhuyu granules or placebo.

	Placebo group ()	Xuefu Zhuyu group ()	All ()
Course of disease (months)
Demographics
Age (years)
Male, (%)	15 (75)	15 (75)	30 (75)
Female, (%)	5 (25)	5 (25)	10 (25)
Race
Han	19	20	39
Other	1	0	1
Smoking habit, (%)	6 (30)	5 (25)	11 (27.5)
Alcohol consumption, (%)	9 (45)	8 (40)	17 (42.5)
Body mass index (kg/m^2)
History of diabetes, (%)	1 (5)	1 (5)	2 (5)
Family history of CHD	3	5	8
Abnormal blood routine, (%)	4/19 (21.1)	5/20 (25)	9/39 (23.1)
Abnormal urine routine, (%)	8/19 (42.1)	7/20 (35)	15/39 (38.5)
Abnormal stool routine, (%)	1/13 (7.7)	0/16 (0)	1/29 (3.4)
Abnormal liver function, (%)	2/19 (10.5)	1/20 (5)	3/39 (7.7)
Abnormal kidney functions, (%)	0/19 (0)	1/20 (5)	1/39 (2.6)
CCS, (%)
0	0 (0)	0 (0)	0 (0)
I	10 (50)	12 (60)	22 (55)
II	10 (50)	8 (40)	18 (45)
SAQ
Physical limitations
Anginal stability
Anginal frequency
Treatment satisfaction
Disease perception
Echocardiography measurements
LVEF
LVED (mm)
Number of vessel stenosis
Coronary 4-vessel stenosis	0 (0)	4 (44.44)	4 (22.22)
Coronary 3-vessel stenosis	2 (22.22)	1 (11.11)	3 (16.67)
Coronary 2-vessel stenosis	3 (33.33)	2 (22.22)	5 (27.78)
Coronary 1-vessel stenosis	4 (44.44)	2 (22.22)	6 (33.33)
Coronary 0-vessel stenosis	0 (0)	0 (0)	0 (0)
Medication
Aspirin	4 (20)	9 (45)	13 (32.5)
Clopidogrel	0 (0)	0 (0)	0 (0)
Beta-blocker	3 (15)	5 (25)	8 (20)
Calcium-channel blocker	8 (40)	6 (30)	14 (35)
Angiotensin receptor blockers	5 (25)	9 (45)	14 (35)
ACE inhibitor or ARB	2 (10)	4 (20)	6 (15)
Nitrate	3 (15)	4 (20)	7 (17.5)

.